Printer Friendly

UNIMED REPORTS RECORD SALES OF MARINOL IN FISCAL YEAR RESULTS

     UNIMED REPORTS RECORD SALES OF MARINOL IN FISCAL YEAR RESULTS
    SOMERVILLE, N.J., Nov. 14 /PRNewswire/ -- Unimed, Inc. (NASDAQ: UMED) today reported revenues for the fiscal year ended Sept. 30, 1991, of $6,405,000, compared with $4.5 million for the fiscal year ended Sept. 30, 1990.  Consolidated net loss for the year totaled $517,000 or 13 cents per share, compared with a year-earlier net loss of $1,601,000 or 50 cents per share.
    Pharmaceutical segment revenues for the fiscal year increased 94 percent to $3,727,000.  Sales of Marinol(R) (dronabinol), Unimed's antinausea pharmaceutical for cancer chemotherapy patients, increased 39 percent to $1,671,000, achieving record levels of $568,000 in the fiscal fourth quarter.  Sales of Serc(R) (betahistine HCl), Unimed's pharmaceutical for recurrent vertigo, increased 17 percent to $769,000. Research contract revenue and license fees increased $1,222,000 to $1,287,000.
    Chemical segment revenues for the fiscal year increased 8 percent to $2,530,000.  Other revenues, principally interest, decreased 62 percent to $148,000.
    "Fiscal 1991 has been a year of exciting accomplishment.  The highlight of our progress has been the establishment of a focused sales and marketing force to co-promote Marinol, increasing awareness and use among key physician specialists," said Harold J. Tenoso, Ph.D., Unimed's chairman and chief executive officer.  "In only five months this expanded effort has increased the quarterly sales rate of Marinol by over 50 percent."
    Unimed also reported progress in its Phase III multicenter trials of Marinol for appetite stimulation and prevention of weight loss in AIDS patients.  Marinol has been granted Orphan Drug status for this use.
    "We have enrolled over 50 percent of our target patient group and we are on schedule for filing a Supplemental New Drug Application by July 1992," Tenoso went on to say.  "We have significant expectations for progress in fiscal 1992 through continued growth in Marinol sales and our efforts to acquire new products.  Our objective is to achieve breakeven performance by the latter half of the fiscal year.
    Unimed, Inc. specializes in the development and marketing of pharmaceuticals with primary emphasis on therapy and supportive care of cancer and AIDS patients.  The company has brought two pharmaceuticals to market and has a portfolio of products in development.
                      UNIMED INC. AND SUBSIDIARIES
      Years ended Sept. 30:        1991        1990
    Total revenues             $6,405,000  $4,500,000
    Net loss                     (517,000) (1,601,000)
    Net loss per share              ($.13)      ($.50)
    -0-           11/14/91
    /CONTACT:  Charles P. Harrison, president of Unimed, 908-526-6894/
    (UMED) CO:  Unimed Inc. ST:  New Jersey IN:  MTC SU:  ERN CK-TS -- NY032 -- 4354 11/14/91 10:51 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 14, 1991
Words:446
Previous Article:PROVIDENT AMERICAN CORPORATION ANNOUNCES THIRD QUARTER RESULTS
Next Article:ENDOTRONICS, INC. SIGNS AGREEMENT WITH GOODWIN INSTITUTE FOR CANCER RESEARCH INC. TO EXPAND CONTRACT PRODUCTION SERVICES
Topics:


Related Articles
UNIMED REPORTS REVENUE GROWTH OF 46 PERCENT IN FISCAL FIRST QUARTER
UNIMED REPORTS HIGHER SALES, EARNINGS COMPARED WITH LOSS FOR FIRST QUARTER
UNIMED REPORTS INCREASED REVENUES FOR THIRD QUARTER, NINE MONTHS; HIGHER SALES AND EARNINGS EXPECTED FOR 1995
UNIMED REPORTS EARNINGS IMPROVEMENT ON HIGHER SALES FOR 1995
UNIMED PHARMACEUTICALS REPORTS HIGHER REVENUES AND EARNINGS IN FIRST QUARTER
Unimed Pharmaceuticals Reports Higher Revenues And Earnings For Second Quarter, Six Months
Unimed Pharmaceuticals Reports Higher Revenues and Earnings for Third Quarter and First Nine Months
Unimed Reports 1996 Results: Earnings Exceed Published Estimates
Unimed Pharmaceuticals Reports 41% Revenue Gain in Third Quarter
Unimed Reports 1996 Results: Earnings Exceed Published Estimates

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters